Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy - Scorecard - MDSpire

Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

  • By

  • Konstantin E. Seifert

  • Hendrik Dinkel

  • Linda Huberth

  • Dorothee Tiedje

  • Jan Gröticke

  • Laura-Maria Krabbe

  • Frederike Tepel

  • Kambiz Rahbar

  • Christof Bernemann

  • Andres J. Schrader

  • Martin Bögemann

  • Martin Janssen

  • Katrin Schlack

  • Barbara Heitplatz

  • January 16, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of Treatment Response in Patients with Locally Advanced Renal Cell Carcinoma Following Previous Systemic Therapy

At a Glance

CategoryDetail
ConditionLocally Advanced Renal Cell Carcinoma (RCC)
Key MechanismsSystemic therapy including checkpoint inhibitors (CPI) and tyrosine-kinase inhibitors (TKI) prior to surgical intervention.
Target PopulationPatients with locally advanced RCC not suitable for immediate surgery.
Care SettingSingle center, University Hospital Muenster, Germany.

Key Highlights

  • Neoadjuvant therapy resulted in tumor size reduction of 13-20%.
  • Median residual viable tumor cells post-therapy was 50%.
  • Nearly half of patients showed downstaging in T-stage after systemic therapy.
  • Surgical feasibility improved with neoadjuvant therapy.
  • No significant benefit from adjuvant therapies in prior trials.

Guideline-Based Recommendations

Diagnosis

  • Tumor biopsy prior to systemic treatment.
  • Clinical and radiological assessments for tumor staging.

Management

  • Systemic treatments include TKI, TKI + CPI, or CPI + CPI for at least one month before surgery.

Monitoring & Follow-up

  • Regular clinical and radiological assessments during therapy.

Risks

  • Postoperative complications assessed using Clavien-Dindo classification.

Patient & Prescribing Data

17 patients with locally advanced RCC, mean age 65 years.

Most patients had clear cell histology; systemic therapy was administered prior to surgical resection.

Clinical Best Practices

  • Conduct interdisciplinary tumor board reviews for treatment planning.
  • Utilize imaging to assess tumor size and response to therapy.
  • Ensure informed consent is obtained prior to treatment initiation.

References

Original Source(s)

Related Content